<DOC>
	<DOCNO>NCT02518945</DOCNO>
	<brief_summary>This single center , prospective , randomize , double blind placebo control study conduct I patient type 1 diabetes.The aim study examine additive effect GLP-1 agonist SGLT2 inhibitor patient type 1 diabetes term possible improve glycemic control , reduce glycemic variability , reduce insulin dosage , additional effect weight loss blood pressure reduction .</brief_summary>
	<brief_title>Dapagliflozin As Additional Treatment To Liraglutide And Insulin In Patients With Type 1 Diabetes</brief_title>
	<detailed_description>This investigation single center , prospective , randomize , double blind placebo control study conduct type 1 diabetic . The study conduct Diabetes - Endocrinology Center WNY , affiliate State University New York Buffalo . Visit 1 : Screening Day ( day -21 ) : - Each patient complete following procedure prior participate study . 1 . Medical History ; 2 . Physical Exam ; 3 . Informed consent . 4 . Baseline lab draw measure CBC , comprehensive metabolic panel , Hba1c , Fructosamine lipid profile . All labs drawn fast state morning 10am . Visit 2 : Randomization Visit ( day -14 ) : After screen visit , subject meet inclusion exclusion criterion participate study period . Randomization do ratio 2:1 ( drug : placebo ) use Microsoft Excel randomization function . Liraglutide obtain Novo Nordisk pharmaceutical . Dapagliflozin/placebo obtain Astra Zeneca pharmaceutical . All subject instruct study staff dose administration study medication . Subjects see registered dietitian review carbohydrate count make assessment carbohydrate intake . A CGM sensor insert patient ask keep 2 week . Detailed instruction change sensor weekly provide insulin titration do control blood sugar 70-180 mg/dl . A urine container collect urine 24 hour measure 24-hour urinary glucose provide ( urine collect one day next visit ) . All subject advise monitor capillary blood glucose finger stick meal bedtime wear CGM constantly first two week last two week study The subject ask keep diary food intake measure carbohydrate intake . For entire duration study , patient maintain diary record hypoglycemia untoward side effect like nausea , change appetite experience . Patients instruct call Diabetes Center endocrinology fellow directly case problem untoward side effect . They specifically ask call hypoglycemia ( blood sugar &lt; 70 mg/dl ) hyperglycemia ( blood sugar &gt; 250 mg/dl ) one occasion . Visit 3 Study Intervention : day 0 : - Subjects come fasting visit . Urine collect . CGM 's related supply collect back . Records blood glucose concentration monitor finger stick CGM previous 14 day obtain assess glycemic control liraglutide insulin treatment . They undergo meal challenge test ( describe ) . Fructosamine assay do day . Two questionnaire namely DSQOLS ( Diabetes Specific Quality Life Scale ) PAID ( problem area Diabetes survey ) complete . Dapagliflozin placebo 5 mg start day meal challenge test . Careful adjustment make insulin dose discretion investigator basis glucose data obtain patient . The target blood glucose 70-180 mg/dl time day night without increase incidence blood glucose &lt; 70mg/dl . Patients return center 7 day . Subjects ask make follow-up appointment primary care physician endocrinologist week completion study i.e . Visit 12 ( Day 84 ) maintain continuity care ensure smooth transition . Visit 4 : Study Intervention day 7 : - Insulin dose adjust base fingerstick blood glucose . Patients assess untoward adverse effect use study drug . The dose dapagliflozin ( placebo ) increase 10 mg daily base investigator 's discretion blood glucose reading . Visits 5-10 : Study Interventions day 14 , 21 , 35 , 49 , 63,70 : - Records blood glucose concentration last 7 day visit 5 6 last 14 day visit collect . Insulin dose adjust discretion study investigator optimize blood sugar control per target mention day 0 visit . Any adverse effect study drug assess . The dose dapagliflozin ( placebo ) increase 10 mg daily base investigator 's discretion still start dose ( i.e . 5 mg dapagliflozin ) time visit 5 , 6 7 . No increase dose medication make visit 6 . CGM fit day 70 stay 2 week till day 84 . Visit 11 ( Day 77 ) : CGM fit day stay 2 week till day 84 . A urine container collect urine 24 hour measure 24-hour urinary glucose provide . They bring urine specimen Day 84 . Subjects allow conduct intervention anytime Day 77 Day 82 choose . Visit 12 : Study Intervention ( day 84 ) . Subjects come fasting visit . Records blood glucose concentration monitor finger stick CGM previous 7 day obtain assess glycemic control . They undergo meal challenge test ( describe ) . Two questionnaire namely DSQOLS PAID complete . CGM related supply 24 hour urinary specimen collect back . After visit , subject discharge study . Labs drawn measure CBC , comprehensive metabolic panel , Hba1c , Fructosamine lipid profile . Careful insulin adjustment make discretion investigator depend upon choose continue liraglutide dapagliflozin optimize blood sugar . Meal challenge test : - In order ass change induce dapagliflozin compare placebo , meal challenge carry end study ( day 0 day 84 ) . ( 910 Calorie High fat High carbohydrate meal several previous paper ) . Dapagliflozin final dose administer day 84 ( 45 min prior meal ) . Sequential blood sample obtain 0 , 15 , 30 , 45 , 60 , 90 , 120 , 150 , 180 , 210 , 240 300 min . Samples 15 , 30 , 45 , 90 , 150 210 min 5 ml 0 , 60 , 120 , 180 , 240 300 min 30 ml ( total volume=210 ml ) . Blood collect indwell intravenous canula superficial forearm vein .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Patients type 1 diabetes mellitus : Fasting cpeptide &lt; 0.1nmol/l insulin therapy 12 month without history diabetic ketoacidosis treatment liraglutide maximal tolerated dos least 6 month prior start study . Willing use continuous glucose monitoring device ( CGM ) regularly measure blood sugar four time daily HbA1c le equal 11 % . Well versed carbohydrate counting Age 1875 year Type 1 diabetes less 12 month . Coronary event procedure ( myocardial infarction , unstable angina , coronary artery bypass , surgery coronary angioplasty ) previous four week Hepatic disease ( transaminase &gt; 3 time normal ) cirrhosis ESRD hemodialysis ; eGFR less 30 ml/min/1.73m2 HIV Hepatitis C positive status Participation concurrent clinical trial Any lifethreatening , noncardiac disease Use investigational agent therapeutic regimen within 30 day study History pancreatitis Pregnancy Inability give informed consent History gastroparesis History medullary thyroid carcinoma MEN 2 syndrome Family history MEN 2 , Family history medullary thyroid cancer , familial medullary thyroid cancer Women childbearing potential use adequate contraception Women pregnant History serious hypersensitivity reaction agent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Type 1 Diabetes</keyword>
	<keyword>Liraglutide</keyword>
	<keyword>Dapagliflozin</keyword>
	<keyword>Triple Therapy</keyword>
</DOC>